PHARMACOKINETICS OF ORAL LIPOIC ACID IN CYSTIC FIBROSIS PATIENTS
囊性纤维化患者口服硫辛酸的药代动力学
基本信息
- 批准号:7605141
- 负责人:
- 金额:$ 1.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2008-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimalsAntioxidantsBloodCessation of lifeChronicComputer Retrieval of Information on Scientific Projects DatabaseCystic FibrosisDoseDrug KineticsElastasesElevationEndopeptidasesFundingFutureGelatinase BGrantInflammationInflammatoryInstitutionLaboratory StudyLungLung diseasesMucous body substanceNumbersOralOxidantsPancreatic ElastasePathologic ProcessesPeptide HydrolasesPurposeResearchResearch PersonnelResourcesSourceThickThioctic AcidUnited States National Institutes of Healthcystic fibrosis airwaycystic fibrosis patientscytokinedithiolefficacy trialviscoelasticity
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Early death remains a hallmark of cystic fibrosis (CF), primarily as a result of progressive lung disease. CF is characterized by lung damage from airways obstructed with thick viscous mucus and exposed to a chronic neutrophilic inflammation with prominent elevations in cytokines, proteases and oxidants. -Lipoic acid (LA) is a dithiol compound with the potential to be of significant benefit to CF patients. In laboratory studies, LA is able to decrease mucus viscoelasticity, downregulate inflammatory cytokines and NF- B, inhibit proteases such as elastase and matrix metalloproteinase-9 (MMP-9) and cause direct and indirect antioxidant effects. Animal studies indicate that LA given systemically results in a significant elevation of airway LA. We hypothesize that CF patients given an oral dose of LA will also show elevations in airway LA levels. LA delivered in this manner may address a number of the pathologic processes within the CF airway. In anticipation of future efficacy trials, the purpose of the current study is to define the airway and blood pharmacokinetics of oral LA in CF patients.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
早期死亡仍然是囊性纤维化(CF)的标志,主要是由于进行性肺部疾病。 CF的特征在于来自被粘稠粘液阻塞的气道的肺损伤,并且暴露于慢性嗜酸性炎症,细胞因子、蛋白酶和氧化剂显著升高。 - 硫辛酸(LA)是一种二硫醇化合物,可能对CF患者有显著益处。 在实验室研究中,LA能够降低粘液粘弹性,下调炎性细胞因子和NF- B,抑制蛋白酶如弹性蛋白酶和基质金属蛋白酶-9(MMP-9),并引起直接和间接的抗氧化作用。 动物研究表明,全身给予LA导致气道LA显著升高。 我们假设给予口服LA的CF患者也会显示气道LA水平升高。 以这种方式递送的LA可以解决CF气道内的许多病理过程。 在未来疗效试验的预期中,本研究的目的是确定CF患者口服LA的气道和血液药代动力学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Frank J. Accurso其他文献
Frank J. Accurso的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Frank J. Accurso', 18)}}的其他基金
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS
PTC124 作为无义突变介导的囊性纤维化的口服治疗药物
- 批准号:
7605118 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
AZTREONAM LYSINATE FOR INHALATION FOR CYSTIC FIBROSIS
赖氨酸氨曲南吸入治疗囊性纤维化
- 批准号:
7605107 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
BIOMARKERS OF DISEASE PROGRESSION IN CHILDREN W/CF IDENTIFIED BY NEWBORN SCREEN
通过新生儿筛查识别患有 CF 的儿童疾病进展的生物标志物
- 批准号:
7605056 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
PHARMACOKINETICS OF 552-02 FOLLOWING 14 DAYS OF DOSING BY INHALATION IN PTS W/CF
PTS W/CF 吸入给药 14 天后 552-02 的药代动力学
- 批准号:
7605119 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
TREATMENT OF NEW ONSET PSEUDOMONAS AERUGINOSA IN YOUNG PTS WITH CYSTIC FIBROSIS
年轻囊性纤维化患者新发铜绿假单胞菌的治疗
- 批准号:
7605113 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
OPEN-LABEL AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS
用于吸入治疗囊性纤维化的开放标签赖氨酸氨曲南
- 批准号:
7605116 - 财政年份:2007
- 资助金额:
$ 1.44万 - 项目类别:
AZTREONAM LYSINATE FOR INHALATION FOR CYSTIC FIBROSIS
赖氨酸氨曲南吸入治疗囊性纤维化
- 批准号:
7374397 - 财政年份:2006
- 资助金额:
$ 1.44万 - 项目类别:
OPEN-LABEL AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS
用于吸入治疗囊性纤维化的开放标签赖氨酸氨曲南
- 批准号:
7374405 - 财政年份:2006
- 资助金额:
$ 1.44万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 1.44万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 1.44万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 1.44万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 1.44万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 1.44万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)